DCGI denied approval for final trial of Sputnik Light to Dr Reddy’s Labs

The application was taken up for discussion on Wednesday. Sputnik Light is a single-dose vaccine.

100
DCGI CDSCO

Last Updated on July 3, 2021 by The Health Master

India’s drug regulator (DCGI) denied permission to Hyderabad-based Dr Reddy’s to conduct phase-3 trials on the Russian vaccine Sputnik Light in India.

The subject expert committee (SEC), a body under the drug regulator, did not find any “scientific rationale” to conduct phase-3 trials and hence did not consider Dr Reddy’s application seeking to carry out trials in India, according to sources familiar with the matter.

The application was taken up for discussion on Wednesday. Sputnik Light is a single-dose vaccine.

Medicine Injection Vaccine
Picture: Pixabay

After launching Sputnik V, Russia introduced a new single-dose vaccine, called Sputnik Light, in May. As in the case of Sputnik, Sputnik Light has also been developed by the Russian ministry of health, the Gamaleya National Research Centre of Epidemiology and Microbiology and the Russian Direct Investment Fund (RDIF).

Sputnik V is a two-dose vaccine made from two components – recombinant adenovirus 26 or Ad26 and adenovirus 5 or Ad5 The first dose (Ad26) is the main vaccine, and the second (Ad5) is a booster shot. The Sputnik Light vaccine is made from Ad26, which is the first part of the Sputnik V vaccine.

Sputnik Light is nothing but just the first dose of Sputnik V. Dr Reddy’s wanted to test immunogenicity, (the extent to which the vaccine can teach the immune system to counter the virus).

As a result of the earlier trials on Sputnik V, the immunogenicity data on both the doses (components) was seen. The data with single dose vaccine was not so great and hence the SEC did not find any rationale to conduct the trial again,” said a source.

India so far has mainly been using two vaccines – Covishield and Covaxin – in its vaccination drive. In May, Dr Reddy’s launched the third vaccine – Sputnik V.

Axio Biosolution gets USFDA nod for Patch for bleeding control

Glenmark gets USFDA nod for generic Lung cancer drug

USFDA okays Tocilizumab for treatment of Covid-19

Zydus Cadila gets tentative nod from USFDA for Pemetrexed for Injection

Cipla gets USFDA nod for Inhalation product

Zydus Cadila gets tentative nod from USFDA for Fingolimod Capsules

NPPA fixes retail prices of 3 formulations

DCGI allows Cipla to import Moderna vaccine in India

First ‘Skin Bank’ set up: Hetero and Rotary Club provide financial…

Axio Biosolution gets USFDA nod for Patch for bleeding control

NITI Aayog releases report on not-for-profit hospital model in India

Govt to start two more Vaccine Testing Laboratories

Telegram
WhatsApp
Facebook
LinkedIn
Google-news

Enter your email address:

Delivered by FeedBurner